Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2029 (octreotide subcutaneous depot) in acromegaly
NCT04125836Phase 3Completed
- Sponsor
- Camurus
- Start
- Oct 2019
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of octreotide hydrochloride in acromegaly, sponsored by Camurus. Primary endpoint: Adverse Events at 52 weeks. Started Oct 2019; status: completed.
02
Drugs
octreotide hydrochloride
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT04125836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04125836.